Silex Systems Limited Overview
Silex Systems is a pre-revenue Australian deep-technology company whose core asset is the SILEX process, a proprietary "third-generation" laser isotope separation technology. The technology was invented at Lucas Heights and is classified by both the Australian and US governments. Silex does not mine or enrich uranium itself. Instead, it commercialises SILEX for uranium through Global Laser Enrichment LLC (GLE), the exclusive licensee, which it owns 51% alongside Cameco (49%). GLE plans to build the Paducah Laser Enrichment Facility (PLEF) in Kentucky. The plant would first re-enrich US Department of Energy (DOE) depleted uranium tails into natural UF6, and later produce LEU, LEU+ and potentially HALEU. The company calls this a "Triple Opportunity" single-site solution.
Silex captures value in three ways: a perpetual royalty of at least 7% on GLE enrichment revenue, up to US$20 million in milestone payments, and its equity share of GLE. Secondary platforms are:
-
Quantum Silicon (Q-Si): enriched silicon-28 for silicon quantum computing
-
Medical Isotope Separation Technology (MIST)
The investment case is binary-leaning. It depends on PLEF licensing (an NRC decision is expected around 2027), the financing and final investment decision (FID), and Cameco's option to step up to 75% of GLE.
Company's own description
In its FY2025 Annual Report and August 2026 Operational Update, Silex describes itself as a technology commercialisation company. Its primary asset is the SILEX laser enrichment technology, originally developed at its Sydney (Lucas Heights) facility. The company states that its strategy is commercialising SILEX across multiple global markets. The primary focus is supplying nuclear fuel reliably and sustainably to the global nuclear power industry, which it describes as a vital enabler of energy security and clean energy (Operational Update, 27 August 2026). Silex lists three application areas:
-
Uranium enrichment and production (nuclear power), via GLE
-
Silicon enrichment (Q-Si) for silicon-based quantum computing
-
Medical isotope enrichment (MIST) for new cancer therapies
Independent characterisation
| Value layer | Mechanism | Status (Oct 2026) |
|---|---|---|
| Equity | 51% of GLE (equity-accounted share of GLE losses flows through Silex P&L) | Active; Silex funds 51% of GLE spend |
| Royalty | Perpetual royalty of ≥7% on GLE enrichment revenue (per company disclosures) | Contingent on PLEF operation (targeted no later than 2030) |
| Milestones | Up to US$20 million in milestone payments from GLE (pilot demonstration, construction start, commercial operation) | US$5 million TRL-6 milestone received December 2025 |
| Option crystallisation | Cameco holds an option to buy an additional 26% of GLE (to 75%). The window started at TRL-6 and runs ~30 months (Shaw and Partners, July 2026) | Open; window expires ~April 2028 |
| Other isotopes | Q-Si plant (Lucas Heights); MIST R&D | Q-Si commissioning late 2026; first samples expected Q1 CY2027 |
| Legacy | Translucent Inc. (cREO semiconductor materials) | Small reporting segment |
Silex is effectively an IP-holding and technology-development company whose valuation rests almost entirely on a US joint venture. Silex holds the majority economic interest in that venture, but under the GLE structure Cameco is the commercial lead. Silex's economics come in layers:
Revenue model and mix
Current revenue is not commercial product revenue. "Revenue from ordinary activities" (A$21.6M in FY2026) is mostly:
-
interest income on cash and term deposits
-
the GLE TRL-6 milestone (≈A$7.6M recognised in FY2026)
-
service and cost-recovery income from GLE and other parties
The mix is effectively 100% interest, licensing and milestones, and services, with 0% product sales of scale. Future revenue would shift to licensing (royalty) and equity earnings from GLE. Q-Si could add product sales of enriched silicon if quantum-computing demand develops.
Value-chain position and customers
Nuclear fuel cycle position: Enrichment technology provider. PLEF would also produce natural UF6, adding conversion-equivalent supply because re-enriching tails yields UF6 directly without mining or conversion. Downstream buyers would be utilities. Under the September 2026 Offtake Agreement, Cameco is the exclusive buyer and seller of all PLEF products.
Q-Si customers: Silicon Quantum Computing Pty Ltd (SQC) and other quantum-device researchers.
MIST: Prospective radiopharmaceutical isotope producers (not yet commercial).
End-markets: Nuclear power fuel (natural UF6, LEU, LEU+, HALEU), quantum computing materials, and nuclear medicine.
Strategy
Stated strategy themes (FY2025 Annual Report; Operational Update, 27 August 2026)
-
Commercialise SILEX for uranium in the US through GLE. The PLEF would be the world's first laser-based uranium enrichment plant and a "single-site solution" for natural UF6, LEU/LEU+ and potentially HALEU.
-
Support US fuel security and the move away from Russian supply. Silex positions PLEF as the only new enrichment facility under NRC licence review (ASX, 23 October 2025) and as part of rebuilding US domestic capacity.
-
Diversify SILEX applications. Q-Si for silicon quantum computing and MIST for medical isotopes.
-
Stay fully funded and debt-free. Funded through FY2028 after the A$149M 2025 raise.
Strategic initiatives (last 24 months)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| TRL-6 pilot demonstration | May–Oct 2025 | Large-scale enrichment testing at Wilmington | Achieved 23 Oct 2025 |
| TRL-7 activities | From late 2025 | Next maturity stage toward commercial design | In progress |
| PLEF licensing | Jun 2025 onward | NRC licence application; EIS by Sep 2026; SER by Jan 2027; mandatory hearing | Under review |
| PLEF site and preliminary works | FY2025–FY2026 | ~700-acre site acquired; initial site clearing | Ongoing |
| US domestic manufacturing base | FY2026 | Expansion of GLE's classified manufacturing operations | Ongoing |
| DOE innovative technology award | Jan 2026 | Up to US$28.5M non-equity support | Contract negotiation/execution |
| Kentucky incentives | Mar 2026 | Up to US$98.9M, performance-based | Preliminary approval |
| Cameco Offtake Agreement | Sep 2026 | Cameco exclusive buyer/seller of all PLEF output | Executed; described as a "key commercial pillar" for FID |
| Q-Si plant | 2023–2026 | Construction complete; commissioning | Samples Q1 CY2027 |
| MIST | Ongoing | Medical isotope R&D | Early stage |
| Capital raise | Aug–Sep 2025 | A$130M placement + A$19.4M SPP | Completed |
Medium-term targets and guidance
First production: GLE aims to begin re-enriching DOE Paducah tails "no later than 2030" (GLE press release, August 2025). A Shaw and Partners site visit in July 2026 reiterated first uranium production on track for 2030. Earlier guidance (March 2025) preserved an option for PLEF commercial operations "as early as 2028". That date has effectively shifted to around 2030.
Scale: Conceptual potential of up to 6 million SWU per year. The company has also described a goal of supplying around 10% of US reactor requirements (smallcaps.com.au summary of ASX, 6 January 2026).
Funding: Fully funded through FY2028 (ASX, 7 August 2025).
Financial guidance: No formal revenue or earnings guidance is given. Consensus EPS for the next financial year is about -A$0.13 (Stockopedia).
Products & Services
SILEX Laser Uranium Enrichment Technology (via GLE) — Silex USA / Silex Systems
| Attribute | Detail |
|---|---|
| Description | Third-generation laser isotope separation. Lasers selectively excite U-235-bearing UF6 molecules for separation. The company claims higher enrichment efficiency and throughput, a smaller footprint and lower capital intensity than second-generation gas centrifuges (ASX, 6 Jan 2026; Kalkine summary of company materials) |
| Maturity | TRL-6 achieved and independently validated, 23 October 2025. TRL-7 activities advancing (H1 FY2026 report) |
| Classification | Classified technology under the Australia–US cooperation agreement |
| Target customers | Utilities (via Cameco as exclusive offtaker/seller); US Government fuel-security programs |
| Pricing model | Silex receives a ≥7% royalty on GLE enrichment revenue plus milestones. PLEF product pricing would follow market SWU and UF6 prices |
| Flagship project | Paducah Laser Enrichment Facility (PLEF), McCracken County, KY |
| Product | Description | Notes |
|---|---|---|
| Natural-grade UF6 | Re-enrichment of DOE high-assay depleted tails to natural assay (0.711% U-235) | First commercial priority. Company materials describe conversion-equivalent supply "for up to three decades" (H1 FY2026 report). GLE targets beginning tails re-enrichment no later than 2030 |
| LEU / LEU+ | Enrichment up to 5% (LEU) and 5–10% (LEU+) for existing and next-generation reactors | Requires additional SILEX capacity. PLEF could reach up to ~6 million SWU per year at full potential (ASX, 23 Oct 2025, company conceptual figure) |
| HALEU | 5–20% U-235 for advanced reactors | Longer-dated option. GLE declined the 2025 DOE HALEU RFP |
Wilmington Test Loop (GLE)
GLE's integrated pilot demonstration facility in Wilmington, NC (on the GNF-A site under licence SNM-1097) performed the TRL-6 large-scale enrichment testing. GLE also operates a classified manufacturing activity, which it is expanding to build a US domestic supply chain for laser and separator hardware (FY2026 Operational Update).
Quantum Silicon (Q-Si) — Silex Systems segment
| Attribute | Detail |
|---|---|
| Description | Isotopically enriched silicon-28 ("Zero-Spin Silicon"), produced by the SILEX process applied to silicon, for spin-qubit silicon quantum computers |
| Facility | First full-scale production module at Lucas Heights; construction started Aug 2023 and completed in 2026. Described as the world's first silicon laser enrichment plant (FY2026 investor materials) |
| Status | Commissioning to complete late 2026; first product samples expected Q1 CY2027 |
| Capacity | Aggregators cite a target of up to ~20 kg/year of Si-28 from the module (ROIC.ai summary of company materials). Treat as indicative |
| Partners | Silicon Quantum Computing Pty Ltd (SQC); UNSW Sydney. The collaboration received a 2025 "Best Industry Research Collaboration" award (ROIC.ai summary) |
| Pricing | — |
| Expansion | Modular expansion possible as quantum computing markets develop (FY2026 results) |
Medical Isotope Separation Technology (MIST) — Silex Systems segment
MIST is early-stage R&D applying laser isotope separation to medical isotopes for cancer therapies. Company disclosures reference ytterbium-176, the precursor for lutetium-177 radiopharmaceuticals. Specifications, customers, timelines and pricing are not publicly disclosed in the sources reviewed.
Translucent cREO — Translucent segment
Translucent's crystalline rare-earth oxide (cREO) technology is a semiconductor materials technology for engineered substrates, such as GaN-on-silicon templates for RF and power devices. Activity is minimal. Pricing and customers are not publicly disclosed.
Financial Narrative
Source basis:
-
Appendix 4E filings for FY2022, FY2023, FY2025 and FY2026
-
FY2025 Annual Report
-
H1 FY2026 Appendix 4D
Silex reports under Australian Accounting Standards (IFRS-aligned). Because GLE is equity-accounted, GLE's spending appears as a single line ("share of net loss of joint venture"). Gross profit, EBITDA and operating income are therefore not meaningful, and Silex does not report them. Those rows are left blank rather than estimated.
Income statement
Notes:
Revenue: FY2024–FY2026 figures are from the FY2025 and FY2026 Appendix 4E. FY2026 revenue includes ≈A$7.6M of GLE TRL-6 milestone revenue (FY2026 results presentation).
Margins. Gross, operating, EBITDA and net margins are not meaningful. Revenue consists of interest, milestones and services, and the net loss exceeds revenue in every year (FY2026 net loss/revenue ≈ -179%).
Revenue CAGR. FY2024–FY2026 revenue CAGR is ≈29% (12.91 → 21.59), but it is driven by one-off milestone income and higher interest income on a larger cash balance. It is not a commercial growth signal.
Commentary.
Loss trend: The net loss quadrupled from A$9.5M (FY2022) to A$42.6M (FY2025). This tracks GLE's ramp-up from the 2021 acquisition through TRL-6 testing (from May 2025), NRC licensing, PLEF site acquisition and preliminary site works.
FY2026 inflection: The FY2026 loss narrowed to A$38.6M. Higher revenue (the US$5M milestone) and higher interest income on the post-raise cash pile partly offset a larger share of GLE losses and higher employee expenses (FY2026 results).
H1 FY2026: Net loss attributable to owners was A$17.94M versus A$18.06M in H1 FY2025 (Appendix 4D, 25 February 2026). Run-rate losses appear to have stabilised around A$35–40M per year pre-FID.
Post-FID outlook: Losses would likely rise sharply after FID unless the PLEF is financed off Silex's balance sheet.
Balance sheet
Notes:
-
Debt excludes small lease liabilities (≈A$0.2–0.6M per aggregators). Silex reports "no corporate debt" (FY2026 results).
-
FY2025 equity is derived from the FY2026 statement that net assets of A$201.2M were "up 121%".
-
FY2025 share count is approximate and pre-placement: 276.7M after the placement and SPP, less ~33.3M placement shares and ~5.0M SPP shares.
Goodwill and intangibles, working capital and the short/long-term debt split are not separately verified. The balance sheet consists mainly of cash plus the equity-accounted investment in GLE. Aggregator data (Digrin/Seeking Alpha, US$) shows total liabilities of only about US$4.7–5.3M across recent periods, confirming a liability-light structure.
Commentary. Cash fell from A$113.1M (FY2024) to A$80.6M (FY2025), reflecting about A$32.5M of net outflow, chiefly contributions to GLE. The August 2025 placement (A$130M at A$3.90) and SPP (A$19.4M) took cash to A$180.7M at 30 June 2026. Management stated that the raise funds Silex "through FY2028" for its 51% share of GLE's commercialisation program (A$188.2M allocated) and other isotope projects (A$26.4M) (ASX, 7 August 2025). NTA per share nearly doubled to 72.26 cents.
Cash flow
Notes:
-
FY2026 change in cash is derived (180.70 - 80.56).
-
The FY2026 equity figure is the A$130M placement plus the ~A$19.4M SPP, before costs.
Operating cash flow, capex and free cash flow are not publicly disclosed in verified primary extracts. Capex at the parent level is small. Aggregators report half-yearly capex below US$0.1M; the Q-Si plant is the main parent-level capital item. Cash contributions to GLE sit in investing cash flows, as investment in a joint venture.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Location |
|---|---|---|
Silex Systems | Parent-company technology development at Lucas Heights: SILEX R&D support for GLE, Q-Si project, MIST, corporate | Sydney (Lucas Heights), NSW |
Silex USA | Holding of Silex's 51% interest in GLE; equity-accounted share of GLE losses and related US activities | North Carolina, USA |
Translucent | Translucent Inc. — cREO (crystalline rare-earth oxide) semiconductor materials technology; minor activity | North Carolina, USA |
Group Entities
| Entity | Ownership | Role |
|---|---|---|
Silex Systems Limited | Listed parent | Owner and developer of SILEX IP |
Silex USA (subsidiary) | 100% | Holds GLE interest |
Global Laser Enrichment Holdings LLC / Global Laser Enrichment LLC | 51% Silex / 49% Cameco. Treated as jointly controlled and equity-accounted (Silex reports a "share of net loss of joint venture") | Exclusive SILEX uranium licensee; Wilmington NC Test Loop; PLEF developer |
Translucent Inc. | 100% (subsidiary) | cREO semiconductor materials |
Results by Segment
| Segment result (AUD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Silex Systems segment result | -3.8 | -1.8 | -1.9 | — | — | — |
Silex USA segment result | -3.8 | -7.7 | — | — | — | — |
Group net loss attributable to owners | -6.93 | -9.46 | -17.36 | -22.73 | -42.56 | -38.62 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from ordinary activities (AUD Mn) | — | — | 12.91 | 12.20 | 21.59 |
Other income (AUD Mn) | — | — | 4.33 | 6.41 | — |
Net loss attributable to members (AUD Mn) | -9.46 | -17.36 | -22.73 | -42.56 | -38.62 |
Basic EPS (A$ cents) | — | — | — | -17.9 | -14.2 |
Diluted EPS (A$ cents) | — | — | — | -17.9 | -14.2 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash, term deposits and dual-currency deposits (AUD Mn) | — | — | 113.09 | 80.56 | 180.70 |
Total corporate debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt (AUD Mn; negative = net cash) | — | — | -113.09 | -80.56 | -180.70 |
Net assets / equity (AUD Mn) | — | — | — | 91.0 | 201.2 |
Net tangible assets per share (A$ cents) | — | — | 55.70 | 38.20 | 72.26 |
Shares on issue (millions) | — | — | — | 243 | 277 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Change in cash and deposits (AUD Mn) | — | — | — | -32.53 | 100.15 |
Equity raised, gross (AUD Mn) | — | — | — | 0 | 149.4 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2025 | FY2026 | Comment |
|---|---|---|---|
ROE (%) | — | -26.4 | Derived: -38.62 / average equity ((91.0 + 201.2)/2) |
Debt/Equity (x) | 0 | 0 | No corporate debt |
Revenue by Region
| Region (revenue, AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from ordinary activities | 12.91 | 12.20 | 21.59 |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Share price | A$4.50 | 7 October 2026 (Kalkine) |
52-week high (approx.) |
| November 2025 |
Year-to-date 2026 | ≈ -44% (to A$4.99) | Simply Wall St / Yahoo, ~September 2026 |
1-year TSR | +26.3% | Simply Wall St, ~September 2026 |
5-year TSR | +213.8% | Simply Wall St, ~September 2026 |
Market cap | ~A$1.25B | At A$4.50 × 277.4M shares |
Enterprise value | ~A$1.07B | Market cap less A$180.7M cash |
ADR (SILXY) | ~US$16 (July 2026); 1 ADR ≈ 5 ordinary shares (inferred from SILXY/SILXF price ratio; verify with depositary) | StockAnalysis |
Share Price
| Price reference (AUD) | May 2025 | Aug 2025 | Nov 2025 | Jan 2026 | Mar 2026 | Jul 2026 | Oct 2026 |
|---|---|---|---|---|---|---|---|
SLX share price | 3.0 | 3.9 | 10.0 | 6.9 | 5.2 | 5.7 | 4.5 |
Valuation Multiples
| Multiple | Silex | Comment |
|---|---|---|
P/E | Not meaningful (loss) | — |
EV/Sales (FY2026) | ≈50x | ~A$1.07B / A$21.6M; not meaningful for valuation |
P/B | ≈6.2x | A$1.25B / A$201.2M net assets. Simply Wall St cited 6.9x at A$4.99 |
Analyst Conclusions
Guidance and expectations
Production timing: GLE targets tails re-enrichment at PLEF no later than 2030.
Licensing: The NRC targets the SER by January 2027, followed by a mandatory hearing.
Q-Si: Commissioning completes late 2026, with samples in Q1 CY2027.
Funding: Silex is funded through FY2028.
Financials: Consensus expects continued losses (EPS ~-A$0.13 next year).
Bull case
-
Technology de-risked, licence in sight. TRL-6 is achieved, the NRC schedule is fixed (SER January 2027), and PLEF is the only new enrichment facility under licence review. A licence would remove the largest non-financial risk.
-
Commercial architecture now in place. The Cameco exclusive offtake (September 2026), US$98.9M of state incentives and up to US$28.5M from DOE support an FID. A Cameco step-up to 75% would crystallise value for Silex's stake and shift capex funding to Cameco.
-
Structural Western supply deficit. Russian supply exits by 2028, conversion and SWU are tight, and ~150M lb of U3O8-equivalent sits in DOE tails. The ≥7% royalty on a multi-million-SWU plant could be material relative to a ~A$1.1B EV.
Bear case
-
Government capital went elsewhere. Losing the US$900M LEU award (January 2026) leaves GLE's owners to fund a roughly US$1.76B+ plant. Silex's 51% share far exceeds its A$180.7M cash, implying dilution unless Cameco exercises its option.
-
Timeline slippage and first-of-a-kind risk. The target has moved from "as early as 2028" to "no later than 2030", and laser enrichment has never run commercially anywhere. Cost and schedule overruns are historically common in nuclear fuel-cycle projects.
-
Valuation and signalling. At ~6x book with no recurring revenue, the stock prices in success. Directors sold ~A$10.8M of shares in February 2026, and the share price has fallen ~55% from its November 2025 peak.
Catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | Direction |
|---|---|---|
| NRC final EIS issuance | Late 2026 (target was September 2026) | Positive if on time |
| 2026 AGM and Chair/CEO address | October–November 2026 | Neutral |
| Q-Si commissioning complete; first Si-28 samples | Late 2026 – Q1 CY2027 | Positive |
| NRC Safety Evaluation Report | January 2027 target | Major positive if on time |
| Mandatory hearing and licence decision | 2,027 | Binary |
| H1 FY2027 results | February 2027 | Cash burn check |
| Cameco 75% option decision | Window to ~April 2028 | Potential major catalyst |
| PLEF feasibility, financing and FID | 2027 (unconfirmed) | Binary |
| DOE contract execution for US$28.5M award; any new federal programs | Ongoing | Positive |
| Uranium, conversion and SWU price trends | Ongoing | Macro |
Analyst verdict
Silex Systems is a rare listed proxy for a genuinely differentiated nuclear fuel-cycle technology. The past 12 months delivered the most significant technical and commercial de-risking in its 38-year history. Independent validation of TRL-6 in October 2025 answered the long-standing question of whether laser enrichment works at scale. The NRC has set a firm review schedule. Kentucky has pledged up to US$98.9M of incentives. In September 2026, Cameco signed up as the exclusive buyer and seller of every product PLEF will make. On the evidence, the technology and commercial-channel risks are materially lower than at any prior point.
The equity has nonetheless de-rated by roughly 55% since November 2025. The January 2026 DOE outcome exposed the central unresolved problem: who funds a first-of-a-kind plant costing around US$1.76B. Silex's A$180.7M of cash funds its share of GLE only through FY2028, not through construction. Unless Cameco exercises its option to 75%, or the project secures substantial government-backed or project-level debt, Silex shareholders face significant dilution before the royalty stream begins around 2030. Timelines have already moved two years to the right, and director selling in February 2026 did little for sentiment.
At about A$1.1B of enterprise value, the market is pricing a meaningful but far from certain probability of PLEF reaching operation. The asymmetry is real. A ≥7% perpetual royalty plus a 51% equity interest in a multi-million-SWU plant, together with Q-Si optionality, could justify broker targets of A$11–13 on success. The downside on delay or financing failure is severe.
Verdict: speculative accumulate for risk-tolerant investors. Position sizing should reflect binary outcomes. The three decisive monitorables are the January 2027 SER, Cameco's option decision, and the PLEF financing structure. Until those resolve, Silex remains an option on US enrichment policy rather than a cash-flow story.
Sources consulted: - Silex Appendix 4E for FY2022, FY2023, FY2025 and FY2026 (ASX / OTC Markets)
-
FY2025 Annual Report summary (sustainabilityreports.com)
-
H1 FY2026 Appendix 4D and Operational Update (25 February 2026)
-
Operational Update (27 August 2026)
-
ASX announcements of 7 August 2025, 18 August 2025, 3 September 2025, 15 September 2025, 17 October 2025, 23 October 2025, 6 January 2026 and 27 March 2026
-
NRC Facility Finder and New Fuel Cycle Facility Licensing pages
-
Federal Register notices 2026-04474 and 2026-05955
-
GLE press release (August 2025)
-
ANS Nuclear Newswire (22 September 2026)
-
World Nuclear News
-
Secondary aggregators (flagged where used): Kalkine, Motley Fool Australia, Simply Wall St, Stockopedia, MarketScreener, InvestSMART, Quartr, StockAnalysis, Digrin, ROIC.ai, TipRanks, Market Index
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age / born |
|---|---|---|---|---|
Dr Michael P. Goldsworthy | CEO & Managing Director, Executive Director | Since Feb 1992 (~34 years) | Co-inventor of SILEX; BSc (Hons), MSc, PhD (physics); FAIP, GAICD. Also Chairman/CEO of Translucent Inc. | Born 1958 |
Julie E. Russell | CFO & Company Secretary | ~15 years (since c.2011) | BBus, CA, MBA, GAICD | — |
Dr Geordie Graetz | Chief Commercial Officer | — | MA, PhD | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Independence | Background |
|---|---|---|---|---|
Craig A. Roy | Non-Executive Chairman | Jan 2019 | Independent | Former Deputy CEO of CSIRO (2010–2018); Chair, Australian Research Data Commons; NED, Sydney Water; Director of GLE Holdings LLC (chaired it until 31 Dec 2023); MBA (Macquarie) |
Dr Michael P. Goldsworthy | CEO / MD | Feb 1992 | Executive | See above |
Christopher D. Wilks | Non-Executive Director | Sep 2007 | — | Finance executive; extensive ASX board experience |
Susan (Susie) Corlett | Non-Executive Director | Nov 2024 | Independent | Public-company NED |
Directors' Remuneration
| Executive | Salary/fees (AUD) | Total compensation (AUD) |
|---|---|---|
Michael Goldsworthy (CEO) | ~770,000 | ~1,180,000 (65% salary / 35% variable incl. equity) |
Julie Russell (CFO) | Not separately verified | ~731,000 |
Craig Roy (Chair) | ~262,000 | ~262,000 |
Board & Management Changes
| Date | Event |
|---|---|
Nov 2024 | Susie Corlett joins the board |
15–16 Dec 2025 | CEO exercises 562,500 options/performance rights; Majenta Holdings (Goldsworthy-associated entity) sells 562,500 shares at ~A$7.48 (~A$4.2M) |
27 Feb 2026 | Director sales: Goldsworthy (indirect) 650,000 shares at A$6.63 (~A$4.3M); Christopher Wilks 850,000 at A$6.63 (~A$5.6M); Craig Roy 129,507 at ~A$6.90 (~A$0.9M) |
Major Shareholders
| Substantial / notable holders (most recent disclosures) | Stake / activity |
|---|---|
Van Eck Associates Corporation | Became substantial holder at 5.39% (>12.8M shares); active trading through Nov 2025 |
State Street Global Advisors | Ceased substantial holding 17 Nov 2025; active buying Dec 2025 (e.g., +2.4M shares, 19 Dec 2025) |
BNY Asset Management | Buying Mar 2026 (small) |
JPMorgan Chase & Co. | Trading around Aug 2025 placement |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Technology | Positioning vs SILEX/GLE |
|---|---|---|---|
Uranium enrichment | Urenco (UK/NL/DE; Urenco USA, Eunice NM) | Gas centrifuge | Incumbent Western leader; expanding US capacity |
Uranium enrichment | Orano (France; planned Oak Ridge, TN "Project IKE") | Gas centrifuge | Major incumbent; US expansion |
Uranium enrichment | Rosatom / TENEX (Russia) | Gas centrifuge | Largest global capacity; US import ban and waivers phasing out |
Uranium enrichment | CNNC (China) | Gas centrifuge | Large domestic supplier |
Uranium enrichment / HALEU | Centrus Energy (US; Piketon, OH) | AC100M centrifuge | Only US-owned enricher; HALEU producer; DOE-backed |
Uranium enrichment | General Matter (US; Paducah lease, Aug 2025) | — | New entrant at the same Paducah locale |
Conversion / UF6 supply | ConverDyn/Honeywell (Metropolis), Cameco (Port Hope), Orano | Conversion | PLEF tails re-enrichment produces natural UF6, competing with conversion-plus-mining supply |
Uranium supply | Kazatomprom, Cameco, NexGen and others | Mining | Tails-derived UF6 competes as secondary supply |
Enriched silicon | Russian centrifuge-enriched Si-28 suppliers (historical), URENCO stable isotopes | Centrifuge | Silex claims a laser route offers secure non-Russian supply |
Medical isotopes (Yb-176) | Isotope suppliers (e.g., Russian centrifuge supply; ASP Isotopes) | Centrifuge / laser (ASP's QE-LIS) | Emerging competition in laser isotope separation |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Company | Revenue | Growth | Margin profile | R&D intensity |
|---|---|---|---|---|
Silex Systems (FY2026) | A$21.6M | +77% | Loss-making (net loss A$38.6M) | Very high (most spend is R&D via GLE) |
Centrus Energy (FY2025) | — | — | Profitable (LEU trading plus HALEU contract) | Moderate |
Urenco (FY2025) | — | — | High EBITDA margins (enrichment oligopoly) | Low–moderate |
Orano (FY2025) | — | — | Profitable | Moderate |



